NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · page 17 of 30
The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.
Regulatory filing · comparison_table · analyze_data · overcrowded density
Slide locked Sign in to view
Slide schematic 7/7
chart 3/3 paragraph 1/1 source-note 1/1 title 2/2
Components 7
bar-vertical line line paragraph source-note action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1